Clinical Trial Update: Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC [Phase 2]

View source ↗

Summary

This update covers a Phase 2 trial comparing second-line irinotecan versus gefitinib in non-small cell lung cancer patients previously treated with docetaxel; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Iressa (gefitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Gachon University Gil Medical Center | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN